Orbimed Advisors LLC
Director at SION; 10% owner at ELVN; 10% owner at PMVP, and 29 more
- Sold, on record
- $647M
- Dollars the filings state
- Form 4 sales
- 75
- Latest Jun 30, 2026
- Form 144 notices
- 27
- Proposed sales
- Companies
- 32
- Filed as an executive or holder
Companies
- SIONSionna Therapeutics, Inc.Director
- ELVNEnliven Therapeutics, Inc.10% owner
- PMVPPMV Pharmaceuticals, Inc.10% owner
- CRVSCorvus Pharmaceuticals, Inc.Director, 10% owner
- PASGPassage BIO, Inc.10% owner
- NPCENeuroPace Inc10% owner
- IRONDisc Medicine, Inc.Director
- TELATELA Bio, Inc.10% owner
- DMRAGalecto, Inc.Shareholder
- Gracell Biotechnologies Inc.Shareholder
- VRNAVerona Pharma plcDirector
- Tricida, Inc.Director, 10% owner
- SWTXSpringWorks Therapeutics, Inc.10% owner
- Repare Therapeutics Inc.Director
- ORICOric Pharmaceuticals, Inc.Director
- INSPInspire Medical Systems, Inc.Director
- ALECAlector, Inc.10% owner
- ViewRay, Inc.10% owner
- PVLAPALVELLA THERAPEUTICS, INC.10% owner
- ADAPYAdaptimmune Therapeutics PLCDirector
- GKOSGLAUKOS CorpDirector
- Audentes Therapeutics, Inc.10% owner
- Roka BioScience, Inc.10% owner
- Loxo Oncology, Inc.Director
- Otonomy, Inc.Director
- INTERCEPT PHARMACEUTICALS INCDirector
- COMPLETE GENOMICS INC10% owner
- AMRNAMARIN CORP PLC\UKDirector
- Anthera Pharmaceuticals IncDirector
- NxStage Medical, Inc.Director, 10% owner
- Biodel IncDirector
- ARYx Therapeutics, Inc.10% owner
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Tricida, Inc.11.8M shares
- ALEC4.2M shares
- ARYx Therapeutics, Inc.2M shares
- NxStage Medical, Inc.2M shares
- Anthera Pharmaceuticals Inc1.6M shares
- PASG1.2M shares
- COMPLETE GENOMICS INC1.2M shares
- INSP1.2M shares
- CRVS1.2M shares
- ELVN1.1M shares
- GKOS1.1M shares
- SION1.1M shares
- ADAPY1M shares
- PVLA1M shares
- AMRN867,100 shares
- TELA620,300 shares
- ViewRay, Inc.521,607 shares
- PMVP500,000 shares
- VRNA482,913 shares
- ORIC454,004 shares
- Loxo Oncology, Inc.447,857 shares
- Audentes Therapeutics, Inc.433,210 shares
- SWTX426,066 shares
- INTERCEPT PHARMACEUTICALS INC308,546 shares
- NPCE263,776 shares
- Biodel Inc180,988 shares
- Roka BioScience, Inc.75,276 shares
- DMRA68,481 shares
- Otonomy, Inc.67,106 shares
- Repare Therapeutics Inc.58,192 shares
- IRON5,738 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale SIONRoutineNov 26 2025
Sold 108,073 shares at $44.55 ($4.8M)
Orbimed Advisors LLC, Director
10b5-1 planSold 2.9% of holdings ($165M position)3.6M shares leftFirst sale on recordFiling
- 2 Form 4 sale SIONRoutineApr 16 +141 days
Sold 510,583 shares at $44.94 ($22.9M)
Orbimed Advisors LLC, Director
10b5-1 planSold 14.5% of holdings ($159M position)3M shares leftFiling
- 3 Form 4 sale SIONRoutineApr 18 +2 days
Sold 55,345 shares at $44.67 ($2.5M)
Orbimed Advisors LLC, Director
10b5-1 planSold 1.8% of holdings ($135M position)3M shares leftFiling
- 4 Form 4 sale SIONRoutineMay 11 +23 days
Sold 292,952 shares at $45.62 ($13.4M)
Orbimed Advisors LLC, Director
10b5-1 planSold 9.9% of holdings ($135M position)2.7M shares left2.7x usual sizeFiling
- 5 Form 4 sale SIONRoutineMay 27 +16 days
Sold 101 shares at $44.49 ($4k)
Orbimed Advisors LLC, Director
10b5-1 planSold 0% of holdings ($119M position)2.7M shares left0x usual sizeFiling
- 6 Form 4 sale ELVNNo planJun 15 +19 days
Sold 281,408 shares at $45.02 ($12.7M)
Orbimed Advisors LLC, 10% owner
No 10b5-1 planSold 3.7% of holdings ($345M position)7.4M shares leftFirst sale on recordFiling
- 7 Form 4 sale ELVNNo planJun 22 +7 days
Sold 860,123 shares at $45.36 ($39M)
Orbimed Advisors LLC, 10% owner
No 10b5-1 planSold 11.6% of holdings ($336M position)6.6M shares leftFiling
- 8 Form 4 sale SIONRoutineJun 30 +8 days
Sold 115,844 shares at $45.50 ($5.3M)
Orbimed Advisors LLC, Director
10b5-1 planSold 4.3% of holdings ($122M position)2.6M shares left1.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (102)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | SION | Director | Form 4 sale | 115,844 | $5.3M | 4.3% | Routine | SEC |
| Jun 22, 2026 | ELVN | 10% owner | Form 4 sale | 860,123 | $39M | 11.6% | No plan | SEC |
| Jun 15, 2026 | ELVN | 10% owner | Form 4 sale | 281,408 | $12.7M | 3.7% | No plan | SEC |
| May 27, 2026 | SION | Director | Form 4 sale | 101 | $4k | 0.0% | Routine | SEC |
| May 11, 2026 | SION | Director | Form 4 sale | 292,952 | $13.4M | 9.9% | Routine | SEC |
| Apr 18, 2026 | SION | Director | Form 4 sale | 55,345 | $2.5M | 1.8% | Routine | SEC |
| Apr 16, 2026 | SION | Director | Form 4 sale | 510,583 | $22.9M | 14.5% | Routine | SEC |
| Nov 26, 2025 | SION | Director | Form 4 sale | 108,073 | $4.8M | 2.9% | Routine | SEC |
| Sep 10, 2025 | PMVP | 10% owner | Form 4 sale | 500,000 | $900k | 7.7% | No plan | SEC |
| Jun 27, 2025 | CRVS | Director, 10% owner | Form 4 sale | 1.2M | $4.9M | 14.1% | No plan | SEC |
| Jun 26, 2025 | PASG | 10% owner | Form 4 sale | 583,657 | $197k | 8.8% | Unusual | SEC |
| May 14, 2025 | NPCE | 10% owner | Form 4 sale | 168,136 | $2.7M | 4.9% | Unusual | SEC |
| Apr 24, 2025 | PASG | 10% owner | Form 4 sale | 235,572 | $79k | 3.4% | Unusual | SEC |
| Mar 24, 2025 | IRON | Director | Form 4 sale | 5,738 | $310k | 3.0% | No plan | SEC |
| Jan 14, 2025 | PASG | 10% owner | Form 4 sale | 223,219 | $142k | 3.1% | No plan | SEC |
| Dec 11, 2024 | PASG | 10% owner | Form 4 sale | 62,276 | $52k | 0.8% | No plan | SEC |
| Dec 6, 2024 | PASG | 10% owner | Form 4 sale | 97,103 | $77k | 1.2% | No plan | SEC |
| Dec 4, 2024 | PASG | Stockholder | Form 144 notice | 3M | $2.7M | Notice | SEC | |
| Sep 19, 2024 | PASG | 10% owner | Form 4 sale | 39,300 | $28k | 0.5% | No plan | SEC |
| Jul 2, 2024 | TELA | 10% owner | Form 4 sale | 428,300 | $2M | 15.1% | No plan | SEC |
| May 3, 2024 | NPCE | 10% owner | Form 4 sale | 29,206 | $409k | 0.9% | No plan | SEC |
| Apr 24, 2024 | NPCE | 10% owner | Form 4 sale | 1,781 | $25k | 0.1% | No plan | SEC |
| Apr 23, 2024 | NPCE | 10% owner | Form 4 sale | 64,653 | $913k | 1.8% | No plan | SEC |
| Dec 12, 2023 | IRON | Shareholder | Form 144 notice | 121,840 | $7.4M | Notice | SEC | |
| Dec 12, 2023 | IRON | Shareholder | Form 144 notice | 315,000 | $19.2M | Notice | SEC | |
| Dec 12, 2023 | IRON | Shareholder | Form 144 notice | 487,360 | $29.7M | Notice | SEC | |
| Nov 22, 2023 | PMVP | Shareholder | Form 144 notice | 87,786 | $198k | Notice | SEC | |
| Oct 2, 2023 | DMRA | Shareholder | Form 144 notice | 37,675 | $27k | Notice | SEC | |
| Oct 2, 2023 | DMRA | Shareholder | Form 144 notice | 585,274 | $421k | Notice | SEC | |
| Oct 2, 2023 | NPCE | Shareholder | Form 144 notice | 288,100 | $2.6M | Notice | SEC | |
| Aug 30, 2023 | DMRA | Shareholder | Form 144 notice | 78,659 | $46k | Notice | SEC | |
| Aug 30, 2023 | DMRA | Shareholder | Form 144 notice | 1.2M | $709k | Notice | SEC | |
| Aug 21, 2023 | DMRA | Shareholder | Form 144 notice | 1.5M | $932k | Notice | SEC | |
| Aug 21, 2023 | DMRA | Shareholder | Form 144 notice | 75,473 | $57k | Notice | SEC | |
| Aug 15, 2023 | DMRA | Shareholder | Form 144 notice | 1.2M | $880k | Notice | SEC | |
| Aug 15, 2023 | DMRA | Shareholder | Form 144 notice | 75,473 | $57k | Notice | SEC | |
| Jul 31, 2023 | DMRA | Shareholder | Form 144 notice | 930,717 | $2.8M | Notice | SEC | |
| Jul 31, 2023 | DMRA | Shareholder | Form 144 notice | 162,153 | $490k | Notice | SEC | |
| Jul 25, 2023 | DMRA | Shareholder | Form 144 notice | 26,700 | $63k | Notice | SEC | |
| Jul 25, 2023 | DMRA | Shareholder | Form 144 notice | 7,800 | $18k | Notice | SEC | |
| Jul 13, 2023 | DMRA | Shareholder | Form 144 notice | 132,100 | $337k | Notice | SEC | |
| Jul 13, 2023 | DMRA | Shareholder | Form 144 notice | 9,800 | $25k | Notice | SEC | |
| Jun 15, 2023 | Gracell Biotechnologies Inc. | Shareholder | Form 144 notice | 305,748 | $1.8M | Notice | SEC | |
| May 15, 2023 | VRNA | Director | Form 4 sale | 482,913 | $9.9M | 11.3% | No plan | SEC |
| May 11, 2023 | VRNA | Shareholder | Form 144 notice | 2.6M | $60.4M | Notice | SEC | |
| Apr 21, 2023 | TELA | 10% owner | Form 4 sale | 192,000 | $1.8M | 6.3% | No plan | SEC |
| Apr 19, 2023 | TELA | Shareholder | Form 144 notice | 192,000 | $2M | Notice | SEC | |
| Apr 17, 2023 | DMRA | 10% owner | Form 4 sale | 68,481 | $128k | 2.8% | No plan | SEC |
| Apr 10, 2023 | DMRA | Shareholder | Form 144 notice | 1,686 | $3k | Notice | SEC | |
| Apr 10, 2023 | DMRA | Shareholder | Form 144 notice | 22,638 | $43k | Notice | SEC | |
| Apr 5, 2023 | DMRA | Shareholder | Form 144 notice | 109,532 | $245k | Notice | SEC | |
| Apr 5, 2023 | DMRA | Shareholder | Form 144 notice | 8,143 | $18k | Notice | SEC | |
| Nov 25, 2022 | Tricida, Inc. | Director, 10% owner | Form 4 sale | 10.3M | $2.2M | 100.0% | Unusual | SEC |
| Aug 9, 2022 | SWTX | 10% owner | Form 4 sale | 274,568 | $10.5M | 4.6% | Unusual | SEC |
| Sep 2, 2021 | Repare Therapeutics Inc. | Director | Form 4 sale | 37,864 | $1.3M | 28.2% | Unusual | SEC |
| Aug 18, 2021 | Repare Therapeutics Inc. | Director | Form 4 sale | 20,328 | $693k | 17.1% | Plan not stated | SEC |
| Jul 1, 2021 | SWTX | 10% owner | Form 4 sale | 15,959 | $1.4M | 0.3% | Plan not stated | SEC |
| Jun 25, 2021 | SWTX | 10% owner | Form 4 sale | 56,634 | $4.8M | 0.9% | Plan not stated | SEC |
| Jun 10, 2021 | SWTX | 10% owner | Form 4 sale | 30,852 | $2.6M | 0.5% | Plan not stated | SEC |
| Jun 9, 2021 | SWTX | 10% owner | Form 4 sale | 48,053 | $4.1M | 0.8% | Plan not stated | SEC |
| Mar 30, 2021 | ORIC | Director | Form 4 sale | 103,424 | $2.4M | 4.5% | Plan not stated | SEC |
| Mar 26, 2021 | ORIC | Director | Form 4 sale | 112,298 | $2.8M | 4.6% | Plan not stated | SEC |
| Mar 15, 2021 | ORIC | Director | Form 4 sale | 238,282 | $7.3M | 8.6% | Plan not stated | SEC |
| Aug 14, 2020 | INSP | Director | Form 4 sale | 92,187 | $10M | 40.0% | Unusual | SEC |
| Aug 11, 2020 | INSP | Director | Form 4 sale | 116,570 | $12.3M | 33.6% | Unusual | SEC |
| Apr 16, 2020 | ALEC | 10% owner | Form 4 sale | 85,414 | $2M | 4.3% | Plan not stated | SEC |
| Apr 9, 2020 | ALEC | 10% owner | Form 4 sale | 379,885 | $9M | 16.5% | Plan not stated | SEC |
| Mar 31, 2020 | ALEC | 10% owner | Form 4 sale | 250,000 | $6.1M | 11.0% | Plan not stated | SEC |
| Mar 25, 2020 | ALEC | 10% owner | Form 4 sale | 138,653 | $3.4M | 6.2% | Plan not stated | SEC |
| Mar 6, 2020 | INSP | Director | Form 4 sale | 500,000 | $41.8M | 59.0% | Unusual | SEC |
| Mar 2, 2020 | ALEC | 10% owner | Form 4 sale | 1.9M | $48.7M | 100.0% | Unusual | SEC |
| Dec 26, 2019 | ALEC | 10% owner | Form 4 sale | 519,385 | $10.2M | 92.8% | Unusual | SEC |
| Dec 17, 2019 | ALEC | 10% owner | Form 4 sale | 954,100 | $17.7M | 90.7% | Unusual | SEC |
| Dec 11, 2019 | Tricida, Inc. | Director, 10% owner | Form 4 sale | 1.5M | $60M | 13.5% | Plan not stated | SEC |
| Nov 27, 2019 | INSP | Director | Form 4 sale | 124,000 | $8.8M | 8.4% | Plan not stated | SEC |
| Mar 8, 2019 | INSP | Director | Form 4 sale | 358,449 | $20.5M | 19.6% | Plan not stated | SEC |
| Aug 20, 2018 | ViewRay, Inc. | 10% owner | Form 4 sale | 521,607 | $5.2M | 88.2% | Unusual | SEC |
| Apr 30, 2018 | PVLA | 10% owner | Form 4 sale | 1M | $6.3M | 96.3% | Unusual | SEC |
| Mar 29, 2018 | ADAPY | Director | Form 4 sale | 1M | $12.1M | 17.0% | Plan not stated | SEC |
| Mar 6, 2018 | GKOS | Director | Form 4 sale | 836,500 | $26.8M | 100.0% | Unusual | SEC |
| Mar 6, 2018 | Audentes Therapeutics, Inc. | 10% owner | Form 4 sale | 433,210 | $15.2M | 10.5% | Plan not stated | SEC |
| Aug 22, 2017 | Roka BioScience, Inc. | 10% owner | Form 4 sale | 75,276 | $114k | 90.7% | Unusual | SEC |
| Aug 12, 2016 | GKOS | Director | Form 4 sale | 292,938 | $9.9M | 93.4% | Unusual | SEC |
| Aug 10, 2016 | Loxo Oncology, Inc. | Director | Form 4 sale | 447,857 | $12.1M | 20.6% | Plan not stated | SEC |
| Nov 30, 2015 | Otonomy, Inc. | Director | Form 4 sale | 67,106 | $1.9M | 3.5% | Plan not stated | SEC |
| Mar 26, 2015 | INTERCEPT PHARMACEUTICALS INC | Director | Form 4 sale | 157,200 | $45.1M | 12.3% | Plan not stated | SEC |
| Aug 26, 2014 | INTERCEPT PHARMACEUTICALS INC | Director | Form 4 sale | 111,258 | $33.2M | 7.0% | Plan not stated | SEC |
| Oct 21, 2013 | INTERCEPT PHARMACEUTICALS INC | Director | Form 4 sale | 40,088 | $2.5M | 2.3% | Plan not stated | SEC |
| Jul 13, 2012 | COMPLETE GENOMICS INC | 10% owner | Form 4 sale | 1.2M | $3.3M | 97.7% | Unusual | SEC |
| Jun 19, 2012 | AMRN | Director | Form 4 sale | 617,100 | $8M | 98.2% | Unusual | SEC |
| Mar 22, 2012 | Anthera Pharmaceuticals Inc | Director | Form 4 sale | 1.5M | $3.8M | 54.7% | Unusual | SEC |
| Dec 13, 2011 | Anthera Pharmaceuticals Inc | Director | Form 4 sale | 56,200 | $375k | 1.9% | Plan not stated | SEC |
| Mar 28, 2011 | AMRN | Director | Form 4 sale | 173,000 | $1.3M | 73.8% | Unusual | SEC |
| Mar 21, 2011 | AMRN | Director | Form 4 sale | 77,000 | $543k | 55.0% | Unusual | SEC |
| Sep 15, 2010 | NxStage Medical, Inc. | Director, 10% owner | Form 4 sale | 54,000 | $876k | 1.4% | Plan not stated | SEC |
| Sep 14, 2010 | NxStage Medical, Inc. | Director, 10% owner | Form 4 sale | 389,900 | $6.5M | 9.4% | Plan not stated | SEC |
| Aug 18, 2010 | NxStage Medical, Inc. | Director, 10% owner | Form 4 sale | 500,200 | $8.5M | 10.6% | Plan not stated | SEC |
| Aug 4, 2010 | NxStage Medical, Inc. | Director, 10% owner | Form 4 sale | 317,700 | $5.2M | 6.3% | Plan not stated | SEC |
| Jul 28, 2010 | NxStage Medical, Inc. | Director, 10% owner | Form 4 sale | 700,556 | $11.8M | 12.3% | Plan not stated | SEC |
| Jun 10, 2009 | Biodel Inc | Director | Form 4 sale | 26,988 | $141k | 1.8% | Plan not stated | SEC |
| May 22, 2009 | ARYx Therapeutics, Inc. | 10% owner | Form 4 sale | 2M | $8M | 59.9% | Unusual | SEC |
| Feb 12, 2008 | Biodel Inc | Director, 10% owner | Form 4 sale | 154,000 | $2.2M | 7.8% | Plan not stated | SEC |